(Q39400103)

11 September 2017

title

Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies (English)

1 reference

11 September 2017

1 reference

1 reference

Rajesh Ringe

1

1 reference

11 September 2017

Sanjay Phogat

series ordinal

2

1 reference

11 September 2017

Jayanta Bhattacharya

series ordinal

3

1 reference

11 September 2017

language of work or name

English

0 references

publication date

6 February 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

426

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

34-41

1 reference

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Structure of an unliganded simian immunodeficiency virus gp120 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Folding of HIV-1 envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

The role of antibodies in HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.01.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2012.01.011

1 reference

11 September 2017

1 reference